Moderate Intensity Aerobic Training in Sub-acute and Chronic Stroke Patients - the Influence on Brain Derived Neurotrophic Factor (BDNF) and Upper-limb Rehabilitation. A Protocol for a Randomized Control Trial and Health Economic Evaluation

Not Applicable

Completed

• Conditions: Stroke
• Interventions: Behavioral: Aerobic Training & UL Motor Training; Behavioral: Non-aerobic training & UL Motor Training

• Registration Number: NCT03701035
• Lead Sponsor: Clare Maguire

Brief Summary

The aim of this study is to evaluate the influence on three different training modalities on the blood concentration levels of a growth factor called Brain Derived Neurotrophic Factor (BDNF) and on the recovery of arm function following in sub-acute and chronic stroke survivors. The training modalities are 1. moderate intensity aerobic training on a bike ergonometer followed by robotic or sensor-based upper-limb training, 2. non-aerobic circuit training followed by robotic or sensor-based upper-limb training 3. circuit training alone.

Detailed Description

Background and Rationale:Brain-derived neurotrophic factor (BDNF) belongs to a group of neurotrophins which influence neuroplasticity by increasing long-term potentiation and axonal and dendritic growth. Levels of serum BDNF are increased following moderate intensity aerobic exercise (MAE) in animal and healthy subjects. The influence of MAE on BDNF following stroke and the resultant efficacy of motor training in this environment remains unclear.

Objective(s):To investigate the influence of MAE on acute and chronic levels of serum BDNF in sub-acute and chronic stroke patients, the efficacy of robotic upper limb or sensor based motor task training in this environment and consequent effect on functional arm recovery compared to the same upper limb training following non-aerobic training circuit training, or non-aerobic circuit training alone To evaluate the cost-effectiveness of the interventions. Study Interventions: Group 1: moderate intensity AE 40 minutes, 3 times weekly followed after 20 minutes break by 40 minutes robotic or sensor-based upper-limb Training. Group2: non-aerobic gait and balance circuit training 40 mins 3 times weekly followed after 20 minutes break by 40 minutes robotic or sensor-based upper-limb training, group 3: 40 minutes non-aerobic gait and balance circuit training.In total 45 participants will be enrolled - 15 in each group.Study Duration:3 monthly Intervention period per intervention group, with a 3 month and 6 month follow-up. .

Study Timeline

• Study First Submitted: 2018-10-07
• Study First Submitted QC: 2018-10-07
• Study Start: 2018-10-08
• Study First Posted: 2018-10-09
• Primary Completion: 2020-09-01
• Study Completion: 2020-09-01
• Status Verified: 2022-12
• Last Update Submitted: 2022-12-28
• Last Update Posted: 2022-12-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 17

Inclusion Criteria

• Hemiplegic stroke ischemic or intracerebral hemorrhagic > 3 months post- stroke
• Active shoulder abduction, wrist and finger extension 10 degrees from a flexed position

Exclusion Criteria

• Contraindications to maximal exercise testing according to the American College of Sports Medicine guidelines
• Severe perceptual problems
• Concurrent neurological diagnoses e.g. Parkinsons disease
• Comorbidities which may interfere with exercise participation
• Significant cognitive impairment < 24 on the Montreal Cognitive Assessment Scale

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Aerobic Training & UL Motor Training	Aerobic Training & UL Motor Training	Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if \< 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 \* weekly, 12 weeks
Non-aerobic Training & UL Motor Training	Non-aerobic training & UL Motor Training	40 minutes non-aerobic gait \& balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 \* weekly, 12 weeks

Primary Outcome Measures

Name	Time	Method
BDNF	12 weeks	Acute (immediate post exercise) and chronic (post-intervention) serum BDNF levels
Action Research Arm Test (ARAT)	12 weeks	A 19-Item standardised assessment of UL function measuring ADLs, coordination \& dexterity.

Secondary Outcome Measures

Name	Time	Method
The Fugl-Meyer Assessment - Upper Extremity Scale (FMA).	12 weeks	Instrument for measuring upper limb impairment after stroke. The Fugl-Meyer Assessment - Upper Extremity Scale (FMA). This is reliable, responsive and valid instrument for measuring upper limb impairment after stroke. Items are scored on a three-point ordinal scale: 0=cannot perform, 1=performs partially, 2=performs fully. Maximal Score 66.
10 meter walking test	12 weeks	A measurement of gait speed
The Montreal Cognitive Assessment (MoCA©).	12 weeks	This is a rapid screen of cognitive performance to detect mild cognitive dysfunction. The test consists of 16 items and 11 categories to assess multiple cognitive domains. The maximal score is 30.
The Fatigue Severity Scale (FSS)	12 weeks	Measures post-stroke-fatigue. This is a 9-item, 7 point linkert scale scale which measures the effect of fatigue on activities and lifestyle. The higher the score the worse the fatigue.
Stroke Impact Scale	12 weeks	A disease specific Quality of Life measure.This is a 59 item measure in which 8 domains are assessed. Each item is a 5-point Linkert scale related to difficulty completing the scale . Summative scores are generated for each domain. A higher score indicates a better Performance.
Trunk Sway in standing with eyes closed	12 weeks	Standing balance
Corsi Block Test	12 weeks	Evaluates visuospatial short-term working memory

Trial Locations

Locations (1)

RehaB clinic for Neurorehabilitation and Paraplegiology; 🇨🇭 Basel, Switzerland